A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized phase II study designed to evaluate the tolerability and
response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell
lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2
systemic therapies.